← Back to Treatments
🏅 FDA Orphan Designation

Ryoncil

remestemcel-L-rknd

Manufacturer: Mesoblast, Inc.

Indicated for:
Acute graft versus host diseaseOrphan

FDA-Approved Indications (1)

treatment of steroid refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older

Indications & Usage

1 INDICATIONS AND USAGE RYONCIL is indicated for the treatment of steroid refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. RYONCIL is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.

💙 Support Programs

View all →
Ryoncil
Mesoblast, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.